Produção Nacional
Revisado por pares
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
2023; Wiley; Volume: 42; Issue: 1 Linguagem: Inglês
10.1002/hon.3240
ISSN1099-1069
AutoresPellegrino Musto, Jon Salmanton‐García, Nicola Sgherza, Rui Bergantim, Francesca Farina, Andreas Glenthøj, Güldane Cengiz Seval, Barbora Weinbergerová, Valentina Bonuomo, Yavuz M. Bilgin, Jaap A. van Doesum, Ozren Jakšić, Benjamín Víšek, Iker Falces‐Romero, Monia Marchetti, Julio Dávila, Sonia Martín‐Pérez, Márcio Nucci, Alberto López‐García, Federico Itri, Caterina Buquicchio, Luisa Verga, Klára Piukovics, Milan Navrátil, Graham P. Collins, Moraima Jiménez, Nicola Stefano Fracchiolla, Jorge Labrador, Lucia Prezioso, Elena Rossi, Natasha Čolović, Stef Meers, Austin Kulasekararaj, Annarosa Cuccaro, Ola Blennow, Toni Valković, Uluhan Sili, Marie‐Pierre Ledoux, Josip Batinić, Francesco Passamonti, Marina Machado, Rafael F. Duarte, Christian Bjørn Poulsen, Gustavo‐Adolfo Méndez, Ildefonso Espigado, Fatih Demırkan, Martin Čerňan, Chiara Cattaneo, Verena Petzer, Gabriele Magliano, Carolina García‐Vidal, Shaimaa El‐Ashwah, Maria Helena Gaíva Gomes-da-Silva, Antonio Vena, Irati Ormazabal‐Vélez, Jens Van Praet, Michelina Dargenio, Cristina De‐Ramón, Maria Ilaria Del Principe, Joyce Marques‐De‐Almeida, Dominik Wolf, Tomáš Szotkowski, Aleš Obr, Gökçe Melis Çolak, Anna Nordlander, Macarena Izuzquiza, Alba Cabirta, Giovanni Paolo Maria Zambrotta, Raúl Córdoba, Павел Зак, Emanuele Ammatuna, Jiřı́ Mayer, Osman İlhan, Ramón García‐Sánz, Martina Quattrone, Elena Arellano, Raquel Nunes Rodrigues, Ziad Emarah, Tommaso Francesco Aiello, Michaela Hanáková, Zdeněk Ráčil, Martina Bavastro, Alessandro Limongelli, Laman Rahimli, Francesco Marchesi, Oliver A. Cornely, Livio Pagano,
Tópico(s)COVID-19 Clinical Research Studies
ResumoPatients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 × 10
Referência(s)